anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a method for isolating, maintaining, proliferating, and differentiating monoclonal cells derived from human salivary gland epithelial stem cells or progenitor cells and a method for preparing extracellular vesicles for treating salivary gland diseases. Specifically, conditions for isolating monoclonal salivary gland epithelial cells were established through an optimized layer separation culture method from a small amount of major or minor salivary gland tissues obtained during surgery or biopsy. In addition, conditions for a culture medium which allow long-term culture of the salivary gland epithelial stem cells or progenitor cells in 2D were established. The cultured stem cells were confirmed to be monoclonal salivary gland basal stem or progenitor cells and yield and cell proliferation ability were confirmed to be excellent. The method for isolating the epithelial stem cells was verified through a characterization analysis, and the method of differentiating the same into various cells in a 3D culture environment was presented. Lastly, a process of obtaining the extracellular vesicles and the healing efficacy thereof were described. It is expected that the monoclonal cells derived from the highly purified human salivary gland epithelial stem cells or the progenitor cells not only can be used as a candidate for cell therapy and the extracellular vesicles for the fundamental treatment of decreased salivary gland function, but also can be broadly used in salivary gland research, comprising disease modeling, pathology research, drug screening, toxicity assessment, and genetic manipulation.
Alzheimer's disease (AD) is a progressive neurodegenerative disease and the most common cause of dementia, characterized by deposition of extracellular amyloid-beta (Aβ) aggregates and intraneuronal hyperphosphorylated Tau. Many AD risk genes, identified in genome-wide association studies (GWAS), are expressed in microglia, the innate immune cells of the central nervous system. Specific subtypes of microglia emerged in relation to AD pathology, such as disease-associated microglia (DAMs), which increased in number with age in amyloid mouse models and in human AD cases. However, the initial transcriptional changes in these microglia in response to amyloid are still unknown. Here, to determine early changes in microglia gene expression, hippocampal microglia from male APPswe/PS1dE9 (APP/PS1) mice and wild-type littermates were isolated and analyzed by RNA sequencing (RNA-seq). By bulk RNA-seq, transcriptomic changes were detected in hippocampal microglia from 6-months-old APP/PS1 mice. By performing single-cell RNA-seq of CD11c-positive and negative microglia from 6-months-old APP/PS1 mice and analysis of the transcriptional trajectory from homeostatic to CD11c-positive microglia, we identified a set of genes that potentially reflect the initial response of microglia to Aβ.
On the morning of Day 1, following an overnight fast of at least 10 hours, a single oral dose of 150 mg omaveloxolone (3 × 50 mg capsules) will be administered with 240 mL of water. No food will be allowed for 4 hours post dose. Pharmacokinetic samples will be obtained from pre dose until 336 hours post dose.
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to oncology and maxillofacial surgery, and can be used for treating initial stages of oral cavity and lip cancer at invasion depth of not more than 7 mm. That is ensured by the peritumoral administration of Technephyt 99mTc radiopharmaceutical preparation with activity of 40–60 MBq a day before the operation to determine the guard lymph node location by single-photon emission computed tomography. 2–4 hours before the operation, a photosensitiser of Photolon or Fotoditazin is introduced in amount of 0.8–1.2 mg/kg of body weight. That is followed by intraoperative single laser irradiation with maximum radiation at wave length 662 nm, power density 200–400 mW/cmand total dose of 100–300 J/cmon tumor growth zones. Duration of light exposure is determined by formula T=D/P, where T is time of light exposure (c), D is required energy density (J/cm), P is power density (W/cm). After the PDT is completed, the radioactive isotope display is followed by the surgical removal of the sentinel node with the surrounding tissue. Pathomorphological examination of a remote sentinel node is performed.EFFECT: method provides the effective treatment with preserving the functional state of the injured organ.1 cl, 7 dwg, 1 ex
The present invention relates to a novel type of human recombinant antibody-like molecules useful in the treatment of i.e. multiple myeloma. These molecules, called Vaccibodies, bind APC and are able to trigger both T cell and B cell immune response. Moreover, Vaccibodies bind divalently to APC to promote a more efficient initiation of an immune response. Hence, a major purpose of the present invention is to induce a strong immune response to render adjuvants redundant. Vaccibodies comprise a dimer of a monomeric unit that consists of a targeting unit with specificity for a surface molecule on APC, connected through a hinge region and a C.gamma.3 domain to a antigenic unit in the COOH-terminal end; the latter being of e.g. B cell lymphoma or myeloma origin (Fig 1), although any origin is possible due to the cassette cloning system in the expression vector. The said molecule is capable of inducing an immune response against multiple myeloma, but extension to a general vaccination strategy for any polypeptid should be feasible. The present invention also relates to a DNA sequence coding for this recombinant antibody based molecule, to expression vectors comprising these DNA sequences, cell lines comprising said expression vectors, to treatment of mammals preferentially by immunization by means of Vaccibody DNA, Vaccibody RNA, or Vaccibody protein, and finally to pharmaceuticals and a kit comprising the said molecules.
PURPOSE:To obtain an antiviral agent showing excellent activity especially against herpes simplex virus and cytomegalovirus, comprising an extract of zygophyllaceous plant as an active ingredient. CONSTITUTION:This antiviral agent comprises 5-100wt.% of an extract of zygophyllaceous plant, preferably obtained by drying stems, leaves or roots preferably of Palo santo belong to the genus Bulunesia, extracting with an organic solvent (e.g. dichloromethane) and concentrating under reduced pressure, as an active ingredient. The extract with a halogenated alkyl or ketone shows excellent antiviral action especially on cytomegalovirus, an extract with a ketone has excellent antiviral action especially on herpes simplex virus I type and an extract with an alcohol exhibits excellent antiviral action especially on herpes simplex virus II type. The antiviral agent can be pharmaceutically manufactured into tablet, powder, granule, capsule, syrup, dispersant, injection, troche, fine granule, external preparation, ointment, suppository, tape agent, etc. The daily does is 0.1-200 mg/kg.
The prevalence of musculoskeletal pain among orthopaedic surgeons is inordinately high. Poor surgical ergonomics and physiological stress have been shown to impair surgical performance and cause injuries. Various approaches, techniques and instruments have been designed to improve surgical outcomes for patients. There has been nominal research in the area of occupational hazards such surgeries impose upon the surgeon. Several studies have demonstrated a higher risk of cervical spondylosis and rotator cuff tears amongst surgeons. However, little has been studied on the impacts of some of these approaches, techniques, and instruments on surgeons' physiologic measures.

The investigator's will use The Hexoskin Smart Vest to capture physiological data from surgeons during the study.
Hepatotoxicity including drug-induced liver injury (DILI) has been reported in patients taking VITRAKVI. 

In patients who received VITRAKVI, increased AST of any grade occurred in 52% of patients and increased ALT of any grade occurred in 45%. Grade 3-4 increased AST or ALT occurred in 3.1% and 2.5% of patients, respectively [see Adverse Reactions (6.1)]. The median time to onset of increased AST was 2.1 months (range: 1 day to 4.3 years). The median time to onset of increased ALT was 2.3 months (range: 1 day to 4.2 years). Increased AST and ALT leading to dose modifications occurred in 1.4% and 2.2% of patients, respectively. Increased AST or ALT led to permanent discontinuation in 3 (1.1%) of patients.

There have been reports in adult patients from clinical studies and postmarketing cases of Grade ≥ 2 increases in ALT and/or AST with increases in bilirubin ≥ 2 x ULN.

Obtain liver function tests (ALT, AST, ALP and bilirubin) before initiation of VITRAKVI and monitor every 2 weeks during the first 2 months of treatment, then monthly thereafter, or more frequently following the occurrence of Grade 2 or greater AST or ALT elevation. Temporarily withhold, reduce the dose, or permanently discontinue VITRAKVI based on severity [see Dosage and Administration (2.4)].
Involves logging in to an online survey and writing in the survey about your everyday experiences. This requires 20-30 minutes of writing a day for 4 consecutive days. You will also provide saliva samples.
Preterm infants in the NICU who are randomized to receive a multisensory intervention, in addition to the standard of care. The multisensory intervention uses recordings of the parents' voices and nurturing touch administered in the NICU during 12 to 23 sessions of standardized, therapist-administered, auditory-tactile stimulation, dispersed over a 2 to 3 week period. The intervention includes 2 components: (1) holding and light pressure containment of the infant against the hospital-gown covered chest of the therapist for tactile and non-specific auditory stimulation simultaneous with (2) playing of mother's voice contingent on infant pacifier sucking. Additionally, a gauze square scented with parent's skin will be used to provide olfactory stimulation.
KEPPRA may cause somnolence and fatigue. Patients should be monitored for these signs and symptoms and advised not to drive or operate machinery until they have gained sufficient experience on KEPPRA to gauge whether it adversely affects their ability to drive or operate machinery.

Somnolence

In controlled trials of adult patients with epilepsy experiencing partial-onset seizures, 15% of KEPPRA-treated patients reported somnolence, compared to 8% of placebo-treated patients. There was no clear dose response up to 3000 mg/day. In a study where there was no titration, about 45% of patients receiving 4000 mg/day reported somnolence. The somnolence was considered serious in 0.3% of KEPPRA-treated patients, compared to 0% in the placebo group. About 3% of KEPPRA-treated patients discontinued treatment due to somnolence, compared to 0.7% of placebo-treated patients. In 1.4% of KEPPRA-treated patients and 0.9% of placebo-treated patients, the dose was reduced, while 0.3% of the KEPPRA-treated patients were hospitalized due to somnolence.

Asthenia

In controlled clinical studies of adult patients with epilepsy experiencing partial-onset seizures, 15% of KEPPRA-treated patients reported asthenia, compared to 9% of placebo-treated patients. Treatment was discontinued due to asthenia in 0.8% of KEPPRA-treated patients as compared to 0.5% of placebo-treated patients. In 0.5% of KEPPRA-treated patients and in 0.2% of placebo-treated patients, the dose was reduced due to asthenia.

Somnolence and asthenia occurred most frequently within the first 4 weeks of treatment. In general, the incidences of somnolence and fatigue in the pediatric partial-onset seizure studies, and in pediatric and adult myoclonic and primary generalized tonic-clonic seizure studies were comparable to those of the adult partial-onset seizure studies.
PURPOSE: A hair dye shampoo using natural materials and a method for manufacturing the same are provided to ensure safety without toxicity, to prevent hair loss, and to maintain silky hair without bleaching or discoloration. CONSTITUTION: A method for manufacturing a hair dye shampoo using natural materials comprises: a step of storing 400g of pulverized Ecliptae Herba in 1L of water at 65-75 deg. C for 12 hours and preparing an Ecliptae Herba extract; a step of storing 400g of pulverized black rice in 1L of water at 65-75 deg. C for 12 hours and preparing a black rice extract; a step of each mixing 120kg of pulverized Polygoni multiflori Radix, Asparagus cochinchinensis MERR. and mulberry, and Acorus calamus L. in 1L of water at 65-75 deg. C for 12 hours and preparing a mixture extract; and a step of mixing 15-25 wt% of the Ecliptae Herba extract, 15-25 wt% of the black rice extract, 40-55 wt% of the mixture extract, 10-15 wt% of surfactant, 1-2 wt% of hydroxyethyl cellulose, and 1-2 wt% of hematoxylin or hematein.
Diabetes is a condition in which the body dose not effectively use sugar so that there is too much sugar in the blood. It is estimated that 15% of the diabetics suffer from diabetic food ulcers at some point. The healing process can be slow and easily to be infected with some pathogens so the patients are at risk in amputation. The wound healing process is a complex mechanism involves the interaction of molecular signals and different cell types. Platelets play important roles in wound healing. When injury occurs platelets are activated with thrombin and clot is formed. In addition to the function of hemostasis, activated platelets release many growth factors that trigger angiogenesis, extracellular matrix production and cytokine release, which is need for wound healing.

Platelet-rich plasma (PRP) is a portion of plasma fraction of autologous blood having a high concentration of thrombocytes. Thrombin induces the activation of PRP and results in the release of multiple growth factors, including platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), insulin-like growth factor (IGF), and transforming growth factor beta (TGF-β). PRP is known for the capacity to stimulate cell proliferation and differentiation. PRP can also interact with macrophage to improve tissue healing and regeneration, and exhibit potent activities against several kinds of pathogens.

Our study will focus on the advantage of PRP for aiding wound healing for diabetes. PRP from autologous blood can be mixed with thrombin in appropriate ratio and inject into the sites around the wound, as adjuvant treatment along with the standard care of chronic diabetic. The wound will be checked 1 to 2 times each week for the evaluation of PRP on clinical application.
Intervention：World Health Organization (WHO) Standardized Regimen group consists of 26 weeks with two phases of treatment. The first is an intensive phase of 8 weeks, and included rifampicin, isoniazid, pyrazinamide, and ethambutol. This is followed by a continuation phase of 18 weeks with the following agents: rifampicin and isoniazid.
The invention is concerned with a kind of dispensation of invigorating the spleen and tonifying the kidney preparation and its preparation method. It relates to raw milkvetch root, raw red sage root, Rhizoma Dioscoreae, raw bighead atractylodes rhizome, broomrape, roud cardamon seed, raw rhubarb, raw liquorice, and so on. Dry, grind, soak, boil out, boil out again, mix about materials to get the said preparation. It bases on traditional Chinese medicine theory and the correlation theory of five parenchymatous viscera. This dispensation is fit for chronic kidney disease without anaphylactic response and side effect. It can release many clinical symptoms, such as spontaneous perspiratio and fatigue, short of breath and want of speech, yellowish complexion and emaciation, inappetence and abdominal distension, improve the kidney function and nutriture to prolong survival time of sufferers. It has low cost and easy preparation technology.
<P>PROBLEM TO BE SOLVED: To provide an oral administration adjuvant composition for pets in order to easily orally administer a drug to the pets such as a dog or a cat without deteriorating the pharmacodynamic effects.  <P>SOLUTION: The oral administration adjuvant composition for the pets comprises (a) a gelling agent, (b) a protein hydrolyzate and (c) water. The oral administration adjuvant composition may further comprise (d) a sugar or a sugar alcohol and may further comprise (e) a flavor. The protein hydrolyzate (b) is preferably a collagen peptide. The sugar alcohol (d) is preferably erythritol.  <P>COPYRIGHT: (C)2009,JPO&INPIT
This is a cohort study that aims to determine the relative risk of developing virologically-confirmed dengue among Philippine children who are eligible to receive dengue vaccine during the DOH Mass Dengue Vaccination. Additionally, it also aims to determine the relative risk of developing severe and/or hospitalized virologically-confirmed dengue among Philippine children who received the Dengue vaccine, describe the epidemiologic trends and characteristics of virologically-confirmed dengue among these children, and assess the performance of simpler tests such as dried blood spots and serum IgG for the assessment of dengue seroprevalence at the population level. We will enroll children who are residents of selected areas in Region 7, Philippines. Children should be eligible to participate in the Department of Health mass dengue vaccination. They will be prospectively venipunctured for baseline dengue serologic status. The blood samples will be stored for serologic testing using neutralization tests and commercial IgG tests. Children in the cohort will be followed up, and those who present with \<5 days of fever will be identified and blood drawn for dengue LAMP and RT-PCR.
The primary objective of this study is to evaluate the efficacy of rasagiline in patients with Parkinson's disease (PD) and apathy. Secondary objectives are 1) to evaluate the affective and cognitive response to rasagiline and their correlates to apathy and 2) to investigate the metabolic and neurophysiologic correlates of the behavioural, cognitive and emotional, aspects of apathy in PD. This will be an exploratory, randomized, double-blind, placebo controlled, parallel-group study. 40 PD patients with apathy and without dementia will be recruited. Rasagiline 1 mg or matching placebo will be administered once daily in conjunction with the subjects' usual oral antiparkinsonian medications for up to 12 weeks. Patients will be evaluated at screening (-7 days) and baseline (0), as well as at weeks 4, 8, and 12. A perfusion SPECT will be performed at baseline and at week 12. The study will be conducted at the Movement Disorders Unit of the Neurology Department at Sant Pau Hospital (Barcelona, Spain).
Fifteen subjects will be randomly selected to undergo S-MRI prior to surgery. These subjects would receive Secretin, administered by IV bolus injection over 1 minute followed by a 30 second saline flush.
The participants randomized to the experimental group will begin outpatient physical therapy services after discharge from inpatient care, on day 4 or 5 post-Total Knee Arthroplasty. The frequency of physical therapy sessions will be 1 x per week throughout the duration of the study period. In addition, this group will utilize in-home exercise equipment daily.
The induction dose for ganciclovir is 5 mg/kg every 12 hours. Full dose maintenance therapy for ganciclovir is 5 mg/kg every 24 hours, 7 days a week.
Advances in molecular tumor diagnostics have transformed cancer care. However, it remains unclear whether precision oncology has the same impact and transformative nature across all malignancies. We conducted a retrospective analysis of patients with human papillomavirus (HPV)-related gynecologic malignancies who underwent comprehensive molecular profiling and subsequent discussion at the interdisciplinary Molecular Tumor Board (MTB) of the University Hospital, LMU Munich, between 11/2017 and 06/2022. We identified a total cohort of 31 patients diagnosed with cervical (CC), vaginal or vulvar cancer. Twenty-two patients (fraction: 0.71) harbored at least one mutation. Fifteen patients (0.48) had an actionable mutation and fourteen (0.45) received a recommendation for a targeted treatment within the MTB. One CC patient received a biomarker-guided treatment recommended by the MTB and achieved stable disease on the mTOR inhibitor temsirolimus for eight months. Factors leading to non-adherence to MTB recommendations in other patient cases included informed patient refusal, rapid deterioration, stable disease, or use of alternative targeted but biomarker-agnostic treatments such as antibody-drug conjugates or checkpoint inhibitors. Despite a remarkable rate of actionable mutations in HPV-related gynecologic malignancies at our institution, immediate implementation of biomarker-guided targeted treatment recommendations remained low, and access to targeted treatment options after MTB discussion remained a major challenge.
PURPOSE:To obtain a solid dentifrice simply cleaning teeth, not requiring use of a toothbrush, by press molding a dentifrice composition comprising at least an abradant, wetting agent and foaming agent. CONSTITUTION:A dentifrice composition comprising at least an abradant, a wetting agent and a foaming agent is press molded. In the case of high content of liquid components, the dentifrice composition is optionally mixed with a binder (one conventionally used for dentifrice). An abradant having fine particles as much as possible is proferable as the abradant and an abradant having particle size used in common dentifrice is sufficiently utilized. Hydroxyapatite is especially preferably used as the abradant because hydroxyapatite has excellent adsorptivity of bacterial plaque and organic substances and properties of readily attaching the surface of teeth and promoting recalcification. The dentifrice is only rubbed in the surface of teeth and lightly washed to clean the teeth.
The Delphi panel will include 10 international experts in sleep and respiratory medicine. Two panelists will serve as co-chairs and eight panelists will serve as section leads for the major topic areas throughout the process. A series of planning sessions will be conducted with the co-chairs and section leads prior to implementation of the survey.
PURPOSE: To make it easy to store, mix and use dental materials by using an ampoule with a closed-type inner room which is given medicine beforehand, introducing a second ingredient into this ampoule, shaking the ampoule so as to mix the two ingredients, and making a mixture. CONSTITUTION: An ampoule 10 possesses an inner room 24 in which a single, first material or ingredient has been put since it was produced. A second material or ingredient is put into the inner room 24 with a syringe or dropper after removing a stopper 18 so as to open an outlet 16 just before mixing work begins. After introducing the second material into the room 24, the stopper 18 is put back to a neck 14 so as to close the outlet 16 and is placed in a compartment of a hard capsule 28. The capsule 28 is then reciprocated by a mixing machine and the ingredients are mixed in the ampoule 10. If it is wished, the mixture made from the two ingredients mixed in the room 24 can be distributed directly to any place where it is desired to be applied by using a transport tube 42 optionally.